Table 1. Patient demographic and neuropathologic features of control, Lewy body disease with intermediate Alzheimer’s pathology (LBD-I-AD), Lewy body disease with Alzheimer’s pathology (LBD-AD), and Parkinson’s disease (PD) subjects.
PMI (post-mortem interval).
| Parameter | Controls | LBD-I-AD | LBD-AD | PD |
|---|---|---|---|---|
| N | 43 | 20 | 29 | 15 |
|
Age (Yrs ± SD) [Range] |
67.1 ± 8.4 [55–83] |
80.9 ± 10.5 [67–90] |
74.3 ± 8.8 [61–93] |
82.8 ± 9.5 [70–100] |
| Gender (% Males) | 60.5 | 65.0 | 62.1 | 73.3 |
|
PMI (Hrs ± SD) [Range] |
25.3 ± 16.9 [3–72] |
14.0 ± 15.1 [3–41] |
20.9 ± 27.18 [2–120] |
22.2 ± 25.4 [2–96] |
| Neocortical Plaques | Absent | Present | Present | Variable |
| Neocortical Neurofibrillary Tangles | Absent | III-IV | V-VI | Absent |
| Midbrain Lewy bodies | Absent | Present | Present | Present |
| Neocortical Lewy bodies | Absent | Present | Present | Absent |